Publications
Able M, Kasper MA, Vick B, Schwach J, Gao X, Schmitt S, Tizazu B, Fischer A, Künzl S, Leilich M, Mai I, Ochtrop P, Stengl A, de Geus MAR, von Bergwelt-Baildon M, Schumacher D, Helma J, Hackenberger CPR, Götze KS, Jeremias I, Leonhardt H, Feuring M and Spiekermann K (2025). Effective eradication of acute myeloid leukemia stem cells with FLT3-directed antibody-drug conjugates. Leukemia, 39, 632-642. PubMed
Schwach J, Abdellatif M and Stengl A (2022). More than Toxins-Current Prospects in Designing the Next Generation of Antibody Drug Conjugates. Front Biosci (Landmark Ed), 27, 240. PubMed
Brandstetter K, Zülske T, Ragoczy T, Hörl D, Guirao-Ortiz M, Steinek C, Barnes T, Stumberger G, Schwach J, Haugen E, Rynes E, Korber P, Stamatoyannopoulos JA, Leonhardt H, Wedemann G and Harz H (2022). Differences in nanoscale organization of regulatory active and inactive human chromatin. Biophys J., 121, 977-990. PubMed
Schwach J, Kolobynina K, Brandstetter K, Gerlach M, Ochtrop P, Helma J, Hackenberger CPR, Harz H, Cardoso MC, Leonhardt H and Stengl A (2021). Site-Specific Antibody Fragment Conjugates for Reversible Staining in Fluorescence Microscopy. Chembiochem., 22, 1205-1209. PubMed